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Objectives: Mefloquine has interesting antischistosomal properties, hence it might be an attractive partner drug
for combination treatment with praziquantel. The aim of this study was to evaluate activities of mefloquine/
praziquantel combinations against Schistosoma mansoni in vitro and in vivo.
Methods: Dose–response relationships were established following exposure of adult S. mansoni to mefloquine,
praziquantel and fixed dose combinations of mefloquine/praziquantel in vitro. S. mansoni-infected mice were
treated orally with selected doses of single drugs and drug combinations 7 weeks post-infection.
Results: We calculated in vitro LC50 values of 0.024 and 1.9 mg/mL for praziquantel and mefloquine, res-
pectively. Mefloquine/praziquantel combinations showed synergistic effects, with combination index (CI)
values ,1 when adult S. mansoni were simultaneously incubated with both drugs in vitro. Reduced viabilities
were also observed when schistosomes were first exposed to mefloquine followed by praziquantel in vitro.
ED50s of 62 mg/kg and 172 mg/kg were determined for mefloquine and praziquantel against adult S.
mansoni in vivo, respectively. Combinations of praziquantel (50 or 100 mg/kg) followed the next day by meflo-
quine (50 or 100 mg/kg) treatment revealed only moderate total worm burden reductions of 47.8%–54.7%. On
the other hand, when both drugs (100 mg/kg each) were either given simultaneously or mefloquine was given
prior to praziquantel, high total and female worm burden reductions of 86.0%–93.1% were observed. For the
later treatment regimen, synergistic effects (CI,1) were calculated when mefloquine and praziquantel were
combined using a fixed dose ratio based on their ED50s.
Conclusions: Combinations of mefloquine and praziquantel may have clinical utility in the treatment of
schistosomiasis.
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Introduction
In the treatment of tuberculosis, cancer or malaria, drugs are
often given in combination to increase their therapeutic advan-
tages.1–3 The clinical effect of a combination of two drugs
should either be the sum (additive behaviour) or ideally even
exceed (synergy) the individual effect of each drug. On the
other hand, for adverse events, antagonism (the effect of the
two drugs being less than the effect of each drug) is preferable.
In addition, combination chemotherapy is a viable therapeutic
strategy to delay the development of drug resistance.4
There is scarce information available as to whether antischis-
tosomal drug combinations provide an increased therapeutic
efficacy over monotherapy. A few clinical trials have evaluated
praziquantel plus oxamniquine combinations and combinations
of praziquantel with an artemisinin derivative.5,6 In the labora-
tory, combinations of ‘something old’ (praziquantel) with ‘some-
thing new’, e.g. novel experimental drugs such as Ro 15-54587 or
nilutamide,8 were studied. However, the great disadvantage of
these combinations (involving novel drug candidates) is the
long drug development process (12–15 years), and therefore
the associated high costs, in the order of $1 billion.9
Another possibility for an antischistosomal drug combination
might be a polytherapy with praziquantel and the antimalarial
drug mefloquine. Several laboratory studies have demonstrated
interesting antischistosomal properties of mefloquine. For
example, a single 200 mg/kg oral dose of mefloquine achieved
a worm burden reduction of 72% in mice harbouring a chronic
Schistosoma mansoni infection.10 In addition, in a randomized,
exploratory open-label trial in Coˆte d’Ivoire in Schistosoma
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haematobium-infected schoolchildren, a mefloquine/artesunate
combination achieved a cure rate of 61% and an egg reduction
rate of 95%.11
The aim of the present study was to evaluate the effect of
mefloquine/praziquantel combinations against S. mansoni
in vitro and in vivo. A preliminary study has already pointed to
significant worm burden reductions following treatment with
praziquantel plus mefloquine in mice infected with Schistosoma
japonicum.12 We determined whether the potency of this drug
combination is additive, antagonistic or synergistic.13 In addition,
we analysed whether mefloquine/praziquantel combinations
should be given simultaneously or in sequence.
Materials and methods
Animals and parasites
Female NMRI mice (n¼125, age¼3 weeks, weight 35 g), obtained from
Harlan Laboratories (Horst, The Netherlands), were kept under standard
conditions (temperature, 258C; humidity, 70%; 12 h light and 12 h
dark cycle) with free access to water and rodent diet in accordance
with the Swiss national and cantonal regulations on animal welfare.
Experiments were approved by the local veterinary agency (permit
2070). S. mansoni cercariae (Liberian strain) were collected after exposing
Biomphalaria glabrata to light for 3 h. Mice were infected subcutaneously
with 80 cercariae.
Drugs
Praziquantel was purchased from Sigma (Buchs, Switzerland), and meflo-
quine hydrochloride was kindly provided by Mepha Pharma AG (Aesch,
Switzerland). For in vitro studies, drugs were dissolved in 100% DMSO
(Fluka, Buchs, Switzerland) to obtain stock solutions of 10 mg/mL. For
in vivo studies, drugs were prepared as suspensions in 7% (v/v)
Tween 80 and 3% (v/v) ethanol before oral administration to mice
(10 mL/kg).
In vitro assay procedures
Preparation of adult S. mansoni and culture conditions
Forty-nine-day-old adult schistosomes, removed by picking from the
hepatic portal system and mesenteric veins from infected NMRI mice,
were washed with PBS (pH 7.4) and kept in RPMI 1640 culture medium
[supplemented with 5% inactivated fetal calf serum (iFCS) and 100 U/mL
penicillin and 100 mg/mL streptomycin (Invitrogen, Carlsbad, CA, USA)] at
378C in an atmosphere of 5% CO2 until use.
Combination chemotherapy studies on adult S. mansoni
in vitro
In a first step, the lethal concentrations (LC100) that kill all schistosomes
within 72 h of in vitro drug exposure and the median effect concen-
trations (LC50) were determined for praziquantel and mefloquine. Drugs
were serially diluted in 24-well plates (Costar) in RPMI 1640 culture
medium and 2 male and 2 female worms were added to each well. Pra-
ziquantel concentrations of 1, 0.5, 0.2, 0.1, 0.05, 0.01 and 0.001 mg/mL
and mefloquine concentrations of 10, 9, 6, 5, 2, 1, 0.5, 0.2, 0.1 and
0.01 mg/mL were tested. Each drug concentration was assessed in dupli-
cates and repeated once (n¼12 worms/drug concentration). For the
interaction studies, mefloquine and praziquantel were added simul-
taneously in a first experiment at a fixed dose ratio based on the
calculated LC50 values (1.9 mg/mL for mefloquine and 0.024 mg/mL for
praziquantel) and 2-fold dilutions were carried out up and down (7.6
and 0.1 mg/mL; 3.8 and 0.05 mg/mL; 1.9 and 0.024 mg/mL; 0.95 and
0.0125 mg/mL; 0.475 and 0.006 mg/mL; and 0.238 and 0.003 mg/mL of
mefloquine and praziquantel, respectively). In addition, we studied a
5-fold dilution of the LC50 value (combination of 0.03 mg/mL mefloquine
and 0.0004 mg/mL praziquantel). Worms were incubated at 378C and 5%
CO2 for 72 h, their viabilities recorded using a microscope (8–40-fold
magnification; Carl Zeiss AG, Germany) and the mean viability of the
12 examined worms calculated as described previously.14 Worms were
classified as dead if no movement was observed for 2 min and worms
had a dark colour. In a second experiment, schistosomes were exposed
to LC50:LC50 (1.9 mg/mL for mefloquine and 0.024 mg/mL for praziquantel)
and 0.5 LC50:0.5 LC50 (0.95 mg/mL for mefloquine and 0.0125 mg/mL for
praziquantel) and drug addition was spaced by the respective half-life of
thedrugs inmice.15,16 Inmore detail, schistosomeswere exposed to (i) pra-
ziquantel followed by mefloquine 1 h post-incubation and (ii) mefloquine
followed by praziquantel 17 h post-exposure. The viabilities of these
worms were assessed 72 h after drug incubation. Worms incubated in
medium containing the highest solvent concentration used (1% DMSO)
served as controls in all experiments.
In vivo studies
Monotherapy
Forty-nine days post-infection, groups of 6–11 mice were treated orally
with subtherapeutic single oral doses of mefloquine (50 and 100 mg/kg)
and praziquantel (50, 100, 150 and 200 mg/kg). Untreated mice served
as controls. At 21 days post-treatment, animals were killed by the CO2
method and dissected. Worms were removed by picking, then sexed and
counted as described in previous publications.17 For the calculation of
the ED50 values, worm burden reductions obtained in recent experiments
with effective doses of mefloquine (200 mg/kg) and praziquantel
(400 mg/kg) were included.10,17
Effect of treatment schedule
We evaluated whether the administration schedule has an influence on
the activity of the drug combination. Six groups of mice were treated
with combinations of mefloquine and praziquantel (50 mg/kg mefloquine
plus 50 mg/kg praziquantel, 100 mg/kg mefloquine plus 100 mg/kg pra-
ziquantel) administered either simultaneously or on subsequent days
(mefloquine followed by praziquantel or praziquantel followed by meflo-
quine). Untreated mice were included as controls. Worms were recovered
as described above.
Effect of drug interactions
To determine the combination dose effect, four groups of mice were
treated with combinations based on their ED50s (1:2.8 ratio and 2-fold
dilutions up and down). The treatment was administered on subsequent
days (mefloquine followed by praziquantel), as this regimen has shown
the highest activity in our experiments in vitro and in vivo. Three weeks
post-treatment, mice were killed and processed as described above.
Scanning electron microscopy study
We collected adult S. mansoni 72 h post-treatment from three mice as
described above, which had been treated with (i) mefloquine (60 mg/kg),
(ii) praziquantel 170 mg/kg, and (iii) mefloquine (60 mg/kg) followed on
the next day by praziquantel (170 mg/kg). Worms were fixed with 2.5%
(v/v) glutaraldehyde in PBS (pH 7.4) for several hours. The schistosomes
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were thenwashed twicewithdouble-distilledwater, dehydrated inascend-
ing ethanol concentrations and critically point dried (Bomar SPC-900;
Tacoma, WA, USA). Finally, worms were sputter coated with 20 nm gold
particles and observed using a high-resolution scanning electron micro-
scope (Phillips XL30 ESEM) at an accelerating voltage of 5 kV.
Statistical analysis
LC50 and ED50 values, combination index (CI), dose reduction index (DRI)
and isobologram plots were calculated using the CompuSyn software
package (ComboSyn, Paramus, NJ, USA). LC50 plots were drawn using
XLfitw (xlfit5, IDBS, Guildford, UK). We used the Kruskal–Wallis (KW)
test to compare the medians of the worm burdens in the monotherapy
versus combination chemotherapy treatment groups [version 2.4.5 Stats-
direct (Cheshire, UK)]. A difference in median was considered to be signifi-
cant at a significance level of 5%.
Results
In vitro studies
Determination of LC50 values of monotherapy
The dose–response curves of mefloquine and praziquantel are
depicted in Figure 1. LC50 values of 0.024 and 1.9 mg/mLwere cal-
culated for praziquantel and mefloquine, respectively. The corre-
sponding LC75 and LC95 values are 0.04 and 0.11 mg/mL for
praziquantel and 3.4 and 9.2 mg/mL for mefloquine, respectively.
Simultaneous drug administration
In Figure 1, the dose–response curve of adult S. mansoni
exposed simultaneously to praziquantel and mefloquine
(LC50:LC50) in vitro is shown. Figure 2 illustrates the combination
dose effect using an isobologram.
Praziquantel/mefloquine combinations showed a synergistic
effect on adult S. mansoni, with CI values ,1 (CI 0.87 at the
LC50 and 0.40 at the LC95). To achieve a 50% reduction of schis-
tosome viability the praziquantel and mefloquine concentrations
could be reduced 2.6- and 2.1-fold, respectively.
Spaced drug administration
When praziquantel and mefloquine were added to the in vitro
cultures with a time lag corresponding to their respective
half-lives, only schistosomes exposed first to mefloquine and
17 h later to praziquantel were affected and showed reduced
viabilities (a viability of 1 for the combination of 1.9 mg/mL
mefloquine and 0.024 mg/mL praziquantel and a viability of 1.5
for the combination of 0.95 mg/mL mefloquine and 0.0125 mg/mL
praziquantel) within 72 h. Parasites exposed to praziquantel for
1 h followed by mefloquine revealed only a slight loss of viability
(viability of 2.0 for both combinations tested) in comparison with
the untreated controls.
In vivo studies
ED50 calculation for mefloquine and praziquantel
For the ED50 calculation we also included results obtained from
previous experiments in our laboratories.10,17 Treatment of
S. mansoni-infected mice with 50, 100 or 200 mg/kg mefloquine
resulted in total worm burden reductions of 44.1, 64.0 (Table 1)
and 93.4%,17 respectively. We calculated an ED50 of 62 mg/kg
and an ED95 of 262 mg/kg.
Worm burden reductions of 13% (50 mg/kg; Table 1) up to
96% (400 mg/kg)10 were observed following treatment with pra-
ziquantel. Praziquantel given at 172 mg/kg and 592 mg/kg is
estimated to achieve worm burden reductions of 50% and
95%, respectively.
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Figure 1. Dose–response curves of mefloquine and praziquantel and
combined mefloquine/praziquantel (LC50:LC50) against adult S. mansoni
in vitro using a viability score.17 The broken line represents the
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Effect of combination treatment regimen on efficacy
Based on the results obtained in our in vitro experiments, which
showed differences depending on the treatment schedule used
(simultaneous or spaced incubation), we were interested
whether these findings could also be documented in vivo. Mice
were divided in three groups. Group 1 was treated with both
drugs simultaneously, group 2 was treated with mefloquine fol-
lowed by praziquantel 24 h later, and group 3 was treated with
praziquantel followed by mefloquine 24 h later. We used sub-
therapeutic doses of 50 and 100 mg/kg for each of the drugs.
The results are summarized in Table 1. When mefloquine and
praziquantel were administered simultaneously at doses of
50 mg/kg each, low total (25.9%) and female (29.0%) worm
burden reductions were observed, which were even lower than
worm burden reductions observed with mefloquine (50 mg/kg)
alone. When both drugs were given at 100 mg/kg simultaneously,
high total and female worm burden reductions of 86.0%
(P¼0.014) and 86.9% (P¼0.091), respectively, were calculated.
High significant worm burden reductions (total worm burden
reduction of 93.1% (P,0.001) and female worm burden
reduction of 93.0% (P¼0.008) were observed when mice were
treated with 100 mg/kg mefloquine followed by 100 mg/kg pra-
ziquantel 24 h later. When half of these doses were given, total
and female worm burden reductions decreased to 61.5% and
58.0%, respectively.
Combinations of praziquantel (50 or 100 mg/kg) followed the
next day by mefloquine (50 or 100 mg/kg) treatment revealed
only moderate total worm burden reductions of 47.8%–54.7%,
which were similar to the results obtained with mefloquine
monotherapy.
Combination dose–effect analysis
We used a constant ratio design based on the ED50s of both drugs
(1:2.8) to analyse whether a mefloquine/praziquantel combi-
nation reveals additive, antagonistic or synergistic effects. Since
the highest worm burden reductions were obtained when prazi-
quantel followedmefloquine administration, this treatment sche-
dule was employed to determine the combination dose effect.
Significant total worm burden reductions of 91.8% and 97.8%
were observed at the two highest concentrations tested
(Table 2). At a dose of 30 mg/kg mefloquine and 85 mg/kg prazi-
quantel, total and female worm burden reductions of 51.6% and
48.8%, respectively, were observed, which were not statistically
significant. At the lowest dose tested (15 mg/kg mefloquine,
42.5 mg/kg praziquantel), low total and female worm burden
reductions of 19.2% and 19.8%, respectively, were achieved. The
ED50 dose of the combination was calculated as 101.8 mg/kg
(26.8 mg/kg mefloquine and 75.1 mg/kg praziquantel, corre-
sponding to a 2.3-fold dose reduction for each drug). A CI of
0.87 was determined at the median dose–effect level. At the
ED75, ED90 and ED95, CI values were below 0.8. Hence, at the
dose ratio for combined praziquantel and mefloquine (1:2.8),
synergistic interactions were observed.
Scanning electron microscopy study
As expected, only very mild tegumental alterations (a handful of
blebs, swelling and fusion of the tegumental ridges) wereTa
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observed on adult schistosomes collected from mice treated
with 60 mg/kg mefloquine and 170 mg/kg praziquantel, respect-
ively (Figure 3a–d). Many worms revealed no tegumental
damage. On the other hand, the majority of worms had
already been expelled from a mouse treated with a combination
of mefloquine and praziquantel 72 h post-treatment. Only a
single worm could be recovered that showed extensive blebbing
on its mid-body (Figure 3e).
Discussion
In several medical fields the search for effective drug combi-
nations has been recognized as an important strategy for a suc-
cessful treatment outcome and to delay drug resistance.1–3 To
our knowledge, we have performed the first analysis of the phar-
macodynamic interactions of mefloquine/praziquantel combi-
nations against S. mansoni. In vitro and in vivo studies were
conducted, which allow assessment of drug combinations in
much more detail than do clinical studies. We used isobologram
and CI analyses, which are popular methods to analyse drug
interactions of combination chemotherapy.13 It is interesting to
note that although several studies have analysed the in vitro
and in vivo antischistosomal efficacy of praziquantel combi-
nations, including the effect of combined treatment of meflo-
quine and praziquantel against S. japonicum,12 in depth
modelling of dose–effect relationships, defining additive
effects, synergy or antagonism of these combinations have not
been carried out to date.
Synergistic interactions were observed in the S. mansoni
mouse model and in vitro when praziquantel was combined
with mefloquine. This finding is encouraging since the control
of schistosomiasis, a chronic and debilitating disease, relies on
a single drug, praziquantel.6,18 The need to develop alternative
treatment options, including drug combinations, has been
repeatedly emphasized because the development of a
praziquantel-resistant schistosome strain is a threat.6,19
It has been suggested to analyse a series of different fixed
dose ratios in combination treatment experiments to confirm
whether two drugs behave additively or synergistically, since it
has been shown that the effect might depend on the ratio of
the drugs used.20 For the evaluation of mefloquine/praziquantel
combinations in vivo we used the median effect analysis only.13
In vitro, however, a range of different dose ratios (including fixed
ratios based on the LC50 presented here) were tested and ana-
lyses of these data confirmed the synergistic properties of the
mefloquine/praziquantel combinations (data not shown).
It is interesting to note that the best results were achieved in
the S. mansoni mouse model when praziquantel treatment fol-
lowed mefloquine. On the other hand, only moderate worm
burden reductions were achieved when praziquantel was admi-
nistered prior to mefloquine. These findings were also observed
in vitro. The effects of praziquantel on schistosomes might play
a role in the antagonistic effects observed when praziquantel
was administered first. Exposure of schistosomes to praziquantel
results in a calcium-dependent contraction of the musculature,
an increase in tension and a disrupted tegument of the
worms.21,22 One could speculate that due to the paralysis and
damage of worms caused by praziquantel, the uptake of meflo-
quine by schistosomes might be decreased, resulting in lowerTa
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activities of the drug combination. On the other hand, the mech-
anism of action of mefloquine on schistosomes has not yet been
elucidated. However, in vivo and scanning electron microscopy
studies have shown that adult schistosomes exposed to meflo-
quine were not affected immediately and only died after 24–
72 h.23 Hence, mefloquine-treated schistosomes might still be
able to interact with praziquantel, resulting in increased activities
of mefloquine/praziquantel combinations.
Since our in vitro and in vivo findings are encouraging, explora-
tory randomized open-label trials have been launched to investi-
gate the effect of mefloquine/praziquantel combinations in
schistosome-infected children. We will treat children first with
mefloquine or mefloquine/artesunate (3 day regimen, in line
with the common malaria treatment schedule), followed by pra-
ziquantel on day 4, since this treatment schedule achieved the
highest activity in vitro and in vivo. In addition, the advantage
of a spaced application of the drugs (in contrast to simultaneous
administration) is that this treatment regimen does not raise
regulatory and review challenges that combination products
would require.24 In a first step we will administer the standard
doses (mefloquine 25 mg/kg, artesunate/mefloquine 300/250 mg
and praziquantel 40 mg/kg); however, since synergistic interactions
were observed in the present study in vivo, we are hoping in a next
step to be able to lower the doses of these drugs to decrease the
prevalence of adverse events and also costs. Of note, we have not
included artesunate in this in vitro and in vivo study, as a preliminary
experiment in our laboratory has shown similar worm burden
reductions (both 86%) of mefloquine/praziquantel/artesunate (all
100 mg/kg administered simultaneously) compared with meflo-
quine/praziquantel (both 100 mg/kg simultaneously) in mice
harbouring adult S. mansoni. Our result is in line with numerous
experiments,whichhavedocumentedagreater sensitivityof juven-
ile schistosomes towards the artemisinins than the adult worm in
laboratory animals.25 However, why increased cure rates have
been observed with mefloquine/artesunate over mefloquine in
our previous study in S. haematobium-infected children cannot be
explained at the moment, as only moderate cure rates were
observed in the group of children treated with artesunate.11
In conclusion, we have demonstrated that a combination of
mefloquine/praziquantel reveals synergistic behaviour in the
treatment of S. mansoni-infected mice and in vitro. The effect
of mefloquine/praziquantel combinations on S. haematobium
should be also studied in detail. To assess the clinical utility of
this drug combination in the treatment of schistosomiasis,
proof-of-concept studies in schistosome-infected children have
been launched.
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